← All trials
NCT06802224
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2025
- Primary completion
- Jul 31, 2028
- Completion date
- Jul 31, 2028
- First posted
- Jan 31, 2025
- Last posted
- Feb 3, 2025
- Enrollment
- 18000
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of California, San FranciscoLead sponsor
- Duke UniversityCollaborator
- University of MichiganCollaborator
- University of VirginiaCollaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Collaborator
- University of MichiganOfficial
- Henry Ford Health SystemCollaborator
- University of WashingtonCollaborator
- University of California, San FranciscoOfficial
- University of MarylandCollaborator
- Wake Forest UniversityCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.